“LIPOSOMAL DRY POWDER INHALER: NOVEL PULMONARY TARGETTED DRUG DELIVERY SYSTEM FOR THE TREATMENT OF LUNG CANCER”
Keywords:Lung Cancer, Lung Targeted Pulmonary Drug Delivery, Liposomal Dry Powder Inhalers, Inhalation Devices, Clinical Trials, Patents, and Future Perspective
Lung cancer is a great evil doer behind mortality around the world. The degree of lung cancer patients in developing nations has grown from 31% to 49.9% over the recent 20 years. Despite current upgrades in lung cancer chemotherapy, the death rate in lung cancer patients is high. Generally, cancer chemotherapy is accompanied by most side effects. If an anticancer drug could deliver only the right site in the right concentration at the right time, cancer could be cured without side effects. A liposomal dry powder inhaler (LDPI) is an innovative strategy to convey drug particles. A dry powder inhaler (DPI) has unique features such as targeted drug delivery, improved bioavailability, and the better therapeutic efficacy of the embedded drug's ability to deliver the drug at a constant rate. This paper emphasizes the utility of liposomes and DPI in lung cancer therapy, commonly used formulation techniques for manufacturing LDPI, various devices used to deliver the therapeutic formulation, and ongoing and recently concluded clinical trials. Patents filed by multiple researchers and the future perspective of LDPI in an innovative drug delivery system and promising systems for administering a wide variety of drugs, including anti-cancer drugs, are described for lung cancer.
Potter J, Higginson IJJLc. Pain experienced by lung cancer patients: a review of prevalence, causes, and pathophysiology. 2004;43(3):247-57.
Kovacevic T, Kovacevic SV, Stanetic M, Kovacevic P, Miljkovic BJJoOPP. Impact of pharmacist’s intervention on decreasing erlotinib interactions in the treatment of lung cancer patients in low resource settings. 2021;27(2):350-8.
Subramanian J, Govindan RJJoco. Lung cancer in never smokers: a review. 2007;25(5):561-70.
Shivapurkar N, Reddy J, Chaudhary PM, Gazdar AFJJocb. Apoptosis and lung cancer: a review. 2003;88(5):885-98.
Zarogoulidis P, Chatzaki E, Porpodis K, Domvri K, Hohenforst-Schmidt W, Goldberg EP, et al. Inhaled chemotherapy in lung cancer: future concept of nanomedicine. 2012;7:1551.
Lee PN, Forey BA, Coombs KJJBc. Systematic review with meta-analysis of the epidemiological evidence in the 1900s relating smoking to lung cancer. 2012;12(1):1-90.
Haasbeek CJ, Senan S, Smit EF, Paul MA, Slotman BJ, Lagerwaard FJJTo. Critical review of nonsurgical treatment options for stage I non-small cell lung cancer. 2008;13(3):309-19.
Fathi Karkan S, Mohammadhosseini M, Panahi Y, Milani M, Zarghami N, Akbarzadeh A, et al. Magnetic nanoparticles in cancer diagnosis and treatment: a review. 2017;45(1):1-5.
Charumathy A, Ubaidulla U, Sinha P, Rathnam GIJCPR. Recent update on liposomes-based drug delivery system. 2022;14(3):22-27.
Bhattacharyya S, Sogali BSJAJPCR. Inhalation Therapy–Approaches and Challenges. 2018;11:9-16.
Shetty A, Srinvasan GJAJPCR. Advancements in dry powder inhaler. 2017;10(2):8-12.
Rajendran R, Balan R, Ganesan N, Thiruvengadam DJIJPPS. Recent modalities in drug delivery via inhalation therapy–An advanced treatment strategy for pulmonary Carcinoma. 2015;7:8-21.
Bonde S, Nair SJIJAP. Advances in liposomal drug delivery system: Fascinating types and potential applications. 2017;9(3):1-7.
Gauch R. It’s Great! Oops, No It Isn’t: Why Clinical Research Can’t Guarantee The Right Medical Answers: Springer; 2008.
Parsons A, Daley A, Begh R, Aveyard PJB. Influence of smoking cessation after diagnosis of early stage lung cancer on prognosis: systematic review of observational studies with meta-analysis. 2010;340.
Takkouche B, Gestal-Otero JJJEjoe. The epidemiology of lung cancer: review of risk factors and Spanish data. 1996;12(4):341-9.
Malhotra J, Malvezzi M, Negri E, La Vecchia C, Boffetta PJERJ. Risk factors for lung cancer worldwide. 2016;48(3):889-902.
Mao Y, Yang D, He J, Krasna MJJSOC. Epidemiology of lung cancer. 2016;25(3):439-45.
Wong M, Lao XQ, Ho K-F, Goggins WB, Tse SLJSr. Incidence and mortality of lung cancer: global trends and association with socioeconomic status. 2017;7(1):1-9.
Zappa C, Mousa SAJTlcr. Non-small cell lung cancer: current treatment and future advances. 2016;5(3):288.
Muhas C, Kumar P, Raja DJIJoP, Sciences P. Etiological factors for the development of lung cancer in non-smokers: an overview. 2019;11:10-6.
Howington JA, Blum MG, Chang AC, Balekian AA, Murthy SCJC. Treatment of stage I and II non-small cell lung cancer: diagnosis and management of lung cancer: American College of Chest Physicians evidence-based clinical practice guidelines. 2013;143(5):e278S-e313S.
Ramalingam S, Belani CJTo. Systemic chemotherapy for advanced non-small cell lung cancer: recent advances and future directions. 2008;13(S1):5-13.
Kelly K, Crowley J, Bunn Jr PA, Presant CA, Grevstad PK, Moinpour CM, et al. Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non–small-cell lung cancer: a Southwest Oncology Group trial. 2001;19(13):3210-8.
Amini A, Yeh N, Gaspar LE, Kavanagh B, Karam SDJRo. Stereotactic body radiation therapy (SBRT) for lung cancer patients previously treated with conventional radiotherapy: a review. 2014;9(1):1-8.
McLachlan JJP. Immune checkpoint inhibitors and their side effects. 2019;51:S17.
Jassem JJTlo. Combined chemotherapy and radiation in locally advanced nonsmall-cell lung cancer. 2001;2(6):335-42.
Burris HJO. Shortcomings of current therapies for non-small-cell lung cancer: unmet medical needs. 2009;28(1):S4-S13.
Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman DJCacjfc. Global cancer statistics. 2011;61(2):69-90.
Cruz CSD, Tanoue LT, Matthay RAJCicm. Lung cancer: epidemiology, etiology, and prevention. 2011;32(4):605-44.
Siegel RL, Miller KD, Goding Sauer A, Fedewa SA, Butterly LF, Anderson JC, et al. Colorectal cancer statistics, 2020. 2020;70(3):145-64.
Ward EM, Sherman RL, Henley SJ, Jemal A, Siegel DA, Feuer EJ, et al. Annual report to the nation on the status of cancer, featuring cancer in men and women age 20–49 years. 2019;111(12):1279-97.
Stewart B, Wild C. IARC Publications Website-World Cancer Report 2014. 2014.
Malik PS, Raina VJTIjomr. Lung cancer: prevalent trends & emerging concepts. 2015;141(1):5.
Mullin TMJFCfDE, Research. Patient-Focused Drug Development Public Meeting. 2012.
Miranda-Filho A, Piñeros M, Bray FJspdm. The descriptive epidemiology of lung cancer and tobacco control: a global overview 2018. 2019;61(3):219-29.
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal AJCacjfc. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. 2018;68(6):394-424.
Rudokas M, Najlah M, Alhnan MA, Elhissi AJMp, practice. Liposome delivery systems for inhalation: a critical review highlighting formulation issues and anticancer applications. 2016;25(Suppl. 2):60-72.
Vanza J, Jani P, Pandya N, Tandel HJDd, pharmacy i. Formulation and statistical optimization of intravenous temozolomide-loaded PEGylated liposomes to treat glioblastoma multiforme by three-level factorial design. 2018;44(6):923-33.
Kong G, Dewhirst MJIJoH. Review hyperthermia and liposomes. 1999;15(5):345-70.
Shurtleff W, Aoyagi A. History of Lecithin and Phospholipids (1850-2016): Extensively Annotated Bibliography and Sourcebook, Including Phosphatides and Liposomes: Soyinfo Center; 2016.
Meure LA, Foster NR, Dehghani FJAP. Conventional and dense gas techniques for the production of liposomes: a review. 2008;9(3):798-809.
Prime D, Atkins PJ, Slater A, Sumby BJAddr. Review of dry powder inhalers. 1997;26(1):51-8.
Willis L, Hayes D, Mansour HMJL. Therapeutic liposomal dry powder inhalation aerosols for targeted lung delivery. 2012;190(3):251-62.
Gaspar MM, Radomska A, Gobbo OL, Bakowsky U, Radomski MW, Ehrhardt CJJoam, et al. Targeted delivery of transferrin-conjugated liposomes to an orthotopic model of lung cancer in nude rats. 2012;25(6):310-8.
Vanza JD, Shah DM, Patel RB, Patel MRJJoDDS, Technology. Afatinib liposomal dry powder inhaler: Targeted pulmonary delivery of EGFR inhibitor for the management of lung cancer. 2022;74:103506.
Islam N, Gladki EJIjop. Dry powder inhalers (DPIs)—a review of device reliability and innovation. 2008;360(1-2):1-11.
Zhang T, Chen Y, Ge Y, Hu Y, Li M, Jin YJAPSB. Inhalation treatment of primary lung cancer using liposomal curcumin dry powder inhalers. 2018;8(3):440-8.
Lo Y-l, Tsai J-c, Kuo J-hJJocr. Liposomes and disaccharides as carriers in spray-dried powder formulations of superoxide dismutase. 2004;94(2-3):259-72.
Franzé S, Selmin F, Samaritani E, Minghetti P, Cilurzo FJP. Lyophilization of liposomal formulations: still necessary, still challenging. 2018;10(3):139.
Shah N, Shah V, Chivate NJJoAPS. Pulmonary drug delivery: a promising approach. 2012(Issue):33-7.
Cipolla D, Gonda I, Chan H-KJTd. Liposomal formulations for inhalation. 2013;4(8):1047-72.
Misra A, Jinturkar K, Patel D, Lalani J, Chougule MJEoodd. Recent advances in liposomal dry powder formulations: preparation and evaluation. 2009;6(1):71-89.
Chougule M, Padhi B, Misra AJAP. Development of spray dried liposomal dry powder inhaler of dapsone. 2008;9(1):47-53.
Joshi M, Misra AJC, pharmacology e, physiology. Disposition kinetics of ketotifen from liposomal dry powder for inhalation in rat lung. 2003;30(3):153-6.
Akbarzadeh A, Rezaei-Sadabady R, Davaran S, Joo SW, Zarghami N, Hanifehpour Y, et al. Liposome: classification, preparation, and applications. 2013;8(1):1-9.
Laouini A, Jaafar-Maalej C, Limayem-Blouza I, Sfar S, Charcosset C, Fessi HJJocS, et al. Preparation, characterization and applications of liposomes: state of the art. 2012;1(2):147-68.
Gubernator JJEoodd. Active methods of drug loading into liposomes: recent strategies for stable drug entrapment and increased in vivo activity. 2011;8(5):565-80.
Wei H, Song J, Li H, Li Y, Zhu S, Zhou X, et al. Active loading liposomal irinotecan hydrochloride: Preparation, in vitro and in vivo evaluation. 2013;8(5):303-11.
Chougule MB, Padhi BK, Jinturkar KA, Misra AJRPodd, formulation. Development of dry powder inhalers. 2007;1(1):11-21.
Shah S, Misra AJDD. Development of liposomal amphotericin B dry powder inhaler formulation. 2004;11(4):247-53.
Shah SP, Misra AJAP. Liposomal amikacin dry powder inhaler: effect of fines on in vitro performance. 2004;5(4):107-13.
Kawasaki H, Shimanouchi T, Kimura YJJoc. Recent development of optimization of lyophilization process. 2019;2019.
Santos D, Maurício AC, Sencadas V, Santos JD, Fernandes MH, Gomes PSJB-P, et al. Spray drying: an overview. 2018:9-35.
Adali MB, Barresi AA, Boccardo G, Pisano RJP. Spray freeze-drying as a solution to continuous manufacturing of pharmaceutical products in bulk. 2020;8(6):709.
Chaurasiya B, Zhao Y-YJP. Dry powder for pulmonary delivery: A comprehensive review. 2020;13(1):31.
Vanza JD, Patel RB, Patel MRJJoDDS, Technology. Nanocarrier centered therapeutic approaches: Recent developments with insight towards the future in the management of lung cancer. 2020;60:102070.
He Z, Ranganathan N, Li PJN. Evaluating nanomedicine with microfluidics. 2018;29(49):492001.
Dolovich MB, Dhand RJTL. Aerosol drug delivery: developments in device design and clinical use. 2011;377(9770):1032-45.
Chellappan DK, Ning QLS, Min SKS, Bin SY, Chern PJ, Shi TP, et al. Interactions between microbiome and lungs: Paving new paths for microbiome based bio-engineered drug delivery systems in chronic respiratory diseases. 2019;310:108732.
Gaspar MM, Bakowsky U, Ehrhardt CJJoBN. Inhaled liposomes–current strategies and future challenges. 2008;4(3):245-57.
Reychler G, Leal T, Roeseler J, Thys F, Delvau N, Liistro GJRm. Effect of continuous positive airway pressure combined to nebulization on lung deposition measured by urinary excretion of amikacin. 2007;101(10):2051-5.
Respaud R, Vecellio L, Diot P, Heuzé-Vourc’h NJEoodd. Nebulization as a delivery method for mAbs in respiratory diseases. 2015;12(6):1027-39.
Steckel H, Eskandar FJEjops. Factors affecting aerosol performance during nebulization with jet and ultrasonic nebulizers. 2003;19(5):443-55.
ClinicalTrials.gov [Internet]. U. S. National Library of Medicine. 2020 December 16. Identifier: NCT03891615, Niraparib in Combination With Osimertinib in EGFR-Mutated Advanced Lung Cancer. [cited 2022 November 08]. Available from: https://www.clinicaltrials.gov/ct2/show/NCT03891615.
ClinicalTrials.gov [Internet]. U. S. National Library of Medicine. 2022 January 24. Identifier: NCT03292133, A Study of EGF816 and Gefitinib in TKI-naïve EGFR-mutant Non-Small Cell Lung Cancer. [cited 2022 November 08]. Available from: https://clinicaltrials.gov/ct2/show/NCT03292133.
ClinicalTrials.gov [Internet]. U. S. National Library of Medicine. 2013 April 11. Identifier: NCT01829373, Lung Cancer Vaccine Plus Oral Dietary Supplement. [cited 2022 November 08]. Available from: https://clinicaltrials.gov/ct2/show/NCT01829373.
ClinicalTrials.gov [Internet]. U. S. National Library of Medicine. 2022 August 25. Identifier: NCT03337399, Stepped Palliative Care Versus Early Integrated Palliative Care in Patients With Advanced Lung Cancer (STEP PC). [cited 2022 November 08]. Available from: https://www.clinicaltrials.gov/ct2/show/NCT03337399.
ClinicalTrials.gov [Internet]. U. S. National Library of Medicine. 2022 March 25. Identifier: NCT03375489, Early Integrated Telehealth Versus In-Person Palliative Care for Patients With Lung Cancer (REACH PC). [cited 2022 November 08]. Available from: https://clinicaltrials.gov/ct2/show/NCT03375489.
ClinicalTrials.gov [Internet]. U. S. National Library of Medicine. 2020 July 13. Identifier: NCT03183232, Safety and Efficiency of γδ T Cell Against Lung Cancer. [cited 2022 November 08]. Available from: https://clinicaltrials.gov/ct2/show/NCT03183232.
ClinicalTrials.gov [Internet]. U. S. National Library of Medicine. 2022 September 6. Identifier: NCT02513563, AZD1775 Plus Carboplatin-Paclitaxel in Squamous Cell Lung Cancer. [cited 2022 November 08]. Available from: https://clinicaltrials.gov/ct2/show/NCT02513563.
ClinicalTrials.gov [Internet]. U. S. National Library of Medicine. 2020 July 22. Identifier: NCT01656460, Stereotactic Body Radiation for Consolidation After Standard Chemoradiation for Stage 3 Lung Cancer. [cited 2022 November 08]. Available from: https://clinicaltrials.gov/ct2/show/NCT01656460.
ClinicalTrials.gov [Internet]. U. S. National Library of Medicine. 2022 October 03. Identifier: NCT03923270, Radiotherapy and Durvalumab/Durvalumab Combo (Tremelimumab/Olaparid) for Small Cell Lung Cancer. [cited 2022 November 08]. Available from: https://clinicaltrials.gov/ct2/show/NCT03923270.
Knight V, Koshkina NV, Waldrep JC, Giovanella BC, Gilbert BEJCc, pharmacology. Anticancer exffect of 9-nitrocamptothecin liposome aerosol on human cancer xenografts in nude mice. 1999;44(3):177-86.
Koshkina NV, Kleinerman ES, Waldrep C, Jia S-F, Worth LL, Gilbert BE, et al. 9-Nitrocamptothecin liposome aerosol treatment of melanoma and osteosarcoma lung metastases in mice. 2000;6(7):2876-80.
Koshkina NV, Waldrep JC, Roberts LE, Golunski E, Melton S, Knight VJCcr. Paclitaxel liposome aerosol treatment induces inhibition of pulmonary metastases in murine renal carcinoma model. 2001;7(10):3258-62.
Khanna C, Anderson PM, Hasz DE, Katsanis E, Neville M, Klausner JSJCIIJotACS. Interleukin‐2 liposome inhalation therapy is safe and effective for dogs with spontaneous pulmonary metastases. 1997;79(7):1409-21.
Gavaldà J, Martín M-T, López P, Gomis X, Ramírez J-L, Rodríguez D, et al. Efficacy of nebulized liposomal amphotericin B in treatment of experimental pulmonary aspergillosis. 2005;49(7):3028-30.
Adler-Moore J, Proffitt RTJJoAC. AmBisome: liposomal formulation, structure, mechanism of action and pre-clinical experience. 2002;49(suppl_1):21-30.
Wong JP, Yang H, Blasetti KL, Schnell G, Conley J, Schofield LNJJocr. Liposome delivery of ciprofloxacin against intracellular Francisella tularensis infection. 2003;92(3):265-73.
Huang Y-Y, Wang C-HJJocr. Pulmonary delivery of insulin by liposomal carriers. 2006;113(1):9-14.
Karathanasis E, Bhavane R, Annapragada AVJJocr. Triggered release of inhaled insulin from the agglomerated vesicles: pharmacodynamic studies in rats. 2006;113(2):117-27.
McLachlan G, Baker A, Tennant P, Gordon C, Vrettou C, Renwick L, et al. Optimizing aerosol gene delivery and expression in the ovine lung. 2007;15(2):348-54.
Griesenbach U, Geddes DM, Alton EJGt. Gene therapy progress and prospects: cystic fibrosis. 2006;13(14):1061-7.
Wang Z , Orszanska H , Finlay W, Inventor; University of Alberta, Assignee; Spray freeze dried liposomal ciprofloxacin powder aerosol drug delivery. United States patent US20060280691A1, 2006 Dec 14.
Stuart SB, Landon WL, Inventor; University of Virginia, Assignee; Compositions and methods for detecting and treating cancer. United States patent US20130330274A1, 2013 Dec 12.
Rolf M et.al., Inventor; Vectron Therapeutics AG Affitech AS, Assignee; Liposomes and Liposomal Compositions for Vaccination and Drug Delivery. United States patent US20070148220A1, 2007 June 28.
Susan N, et al, Inventor; Johnson and Johnson Consumer Inc, Assignee. Method of Manufacturing Liposomes. United States patent US20020119188A1, 2002 Aug 29.
Gregory G et al, Inventor; UK Secretary of State for Defence, Assignee. Method of forming liposomes. United States patent US9675554B1, 2017 Jun 13.
Ian M et al, Inventor; Arbutus Biopharma Corp, Assignee. Systems and Methods for Manufacturing Liposomes. United States patent US9005654B2, 2015 Apr 14.
Paul RM, et al, Inventor; Elan Pharmaceuticals LLC Transave LLC, Assignee. Encapsulation of bioactive complexes in liposomes. United States patent US7491409B1, 2009 Feb 17.
How to Cite
Copyright (c) 2022 MANSING PATIL, PINKAL PATEL
This work is licensed under a Creative Commons Attribution 4.0 International License.